# Borealis Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/borealis-biosciences

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.borealisbio.com
- Total disclosed funding: $180M
- Latest round: Series A (Dec 19, 2024)
- Investors on record: 3

## About

Founded in 2024 by David Powell, and based in British Columbia, Canada, Borealis Biosciences, Inc. operates as a biotechnology research company that develops RNA drugs for treating kidney diseases. In December 2024, Borealis Biosciences raised USD 30 million in series A funding led by new investor Westlake Village BioPartners.

Borealis Biosciences is a company focused on developing RNA medicines to address kidney diseases and potentially other conditions. It was established based on the belief that recent scientific and translational advancements make RNA-based therapies viable for treating these diseases. The company is supported by Versant Ventures and Novartis AG, with whom it has a strategic collaboration.

The company intends to use the December 2024 funding to advance its RNA-based therapeutic programs targeting kidney diseases.

## Funding rounds

- Series A, Dec 19, 2024, $30M — Westlake Village BioPartners
- Series A, Aug 22, 2024, $150M — Versant Ventures, Novartis

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Novartis — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A